HFCL Limited Strong Q3 FY26 Results Driven by Global Demand and Product Innovation

HFCL Limited announced robust Q3 FY26 results, driven by strong global demand for optical fiber and continued expansion in its product and defense portfolios. The company reported a revenue of ₹1210.79 Cr, with EBITDA at ₹243.52 Cr and PAT at ₹102.37 Cr. The order book stands strong at ₹11,125 crore, reflecting healthy revenue visibility. Capacity expansions in optical fiber and cables are progressing as planned.

Financial Performance Highlights

HFCL Limited showcased a strong financial performance in Q3 FY26. Key highlights include:

  • Revenue:₹1210.79 Cr
  • EBITDA:₹243.52 Cr, with a margin of 20.11%
  • PAT:₹102.37 Cr, with a margin of 8.45%

The company’s order book stood at ₹11,125 crore as of December 31, 2025, providing healthy revenue visibility.

Business Segment Performance

The company witnessed improvements across its business segments:

  • The global optical fiber cable industry is experiencing a demand recovery, boosting HFCL’s export orders to approximately USD 192 million. Exports contribute to 27% of revenues.
  • HFCL secured key defense orders across radars, electronic fuzes, and electro-optic systems, including a domestic contract for thermal cameras.

Capacity Expansion and Technological Advancements

HFCL is focused on expanding its production capabilities:

  • OFC capacity is set to increase from 30.5 mn fkm to 42.36 mn fkm by June 2026.
  • The company has developed a 3456-fibre Micro Duct IBR cable, representing a technological advancement.

Strategic Focus and Future Outlook

HFCL is strategically positioned to capitalize on future growth opportunities through:

  • Focusing on high-growth areas such as data centers and defense.
  • Expanding manufacturing capabilities and strengthening R&D.
  • Increasing engagement with private and export customers.

Source: BSE

Previous Article

Adani Enterprises 9M FY26 Results Show Strong Performance, Navi Mumbai Airport Operations Begin

Next Article

Natco Pharma Receives Tentative US FDA Approval for Erdafitinib Tablets